title: Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
abstract: Individuals with familial Parkinson's disease (PD) due to a monogenic defect can show considerable clinical and neuropathological variability. To identify factors underlying this variability, histopathological analysis was performed in two clinically different A53T alpha-synuclein heterozygotes from Family H, a multigenerational alpha-synuclein A53T kindred. To determine whether additional genetic factors could contribute to phenotypic variability, Family H and another multigenerational A53T kindred were analyzed for parkin polymorphisms. We identified a previously described variant in parkin exon 4 associated with increased PD risk (S167N). The two A53T heterozygotes had markedly different neuropathology and different parkin genotypes: A N167 homozygote had early onset rapidly progressive disease, early dementia, myoclonus and sleep disorder, while a S167 homozygote had late onset, slowly progressive disease and late dementia. Both had brainstem, cortical, and intraneuritic Lewy bodies (LB). The N167 individual had widespread cortical neurofibrillary degeneration, while the S167 individual had only medial temporal lobe neurofibrillary degeneration. The N167 individual had severe neuronal loss in CA2 associated with Lewy neurites (LN), while the S167 individual had severe neuronal loss in CA1 associated with TDP-43 immunoreactive neuronal inclusions. These findings implicate TDP-43 in the pathology of familial PD and suggest that parkin may act as a modifier of the A53T alpha-synuclein phenotype of familial PD. Furthermore, they suggest a mechanism by which a rare genetic variant that is associated with a minor increase of PD risk in the heterozygous state may, in the homozygous state, exacerbate a disease phenotype associated with a highly penetrant dominant allele.
authors.affiliation: Department of Neurology, University of Thessaly Medical School, Papakyriazi 22, Larissa, 41222, Greece. emarkopo@med.uth.gr
authors.forename: K
authors.initials: K
authors.lastname: Markopoulou
authors.forename: D W
authors.initials: DW
authors.lastname: Dickson
authors.forename: R D
authors.initials: RD
authors.lastname: McComb
authors.forename: Z K
authors.initials: ZK
authors.lastname: Wszolek
authors.forename: L
authors.initials: L
authors.lastname: Katechalidou
authors.forename: L
authors.initials: L
authors.lastname: Avery
authors.forename: M S
authors.initials: MS
authors.lastname: Stansbury
authors.forename: B A
authors.initials: BA
authors.lastname: Chase
mesh_terms: D001921:Brain / Q000473:pathology*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000235:genetics* / Q000473:pathology* / Q000503:physiopathology*; D010375:Pedigree; D010641:Phenotype; D018807:Polymorphism, Single-Stranded Conformational; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*; D051844:alpha-Synuclein / Q000235:genetics*
chemical_list: C497604:SNCA protein, human; D051844:alpha-Synuclein; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein